Pipeline

Crestone is a clinical stage company focused on developing small molecule drugs for serious bacterial infections. The R&D pipeline includes several programs that address areas of significant and growing unmet medical need, all with novel mechanism of action agents.

Program

CRS3123 for C. difficile

Program

CRS0540 Gram-positives

Program

CRS0393 NTM/TB

Pipeline Progress

Completed Current Activities
ProjectDiscoveryLead OptimizationIND EnabledPhase IPhase IIPhase III

CRS3123 for C. difficile

MetRS inhibitor, narrow spectrum, blocks growth, toxin production, and sporulation

DiscoveryLead Opt.IND EnablingPhase IPhase IIPhase III

CRS0540 Gram-positives

PolC inhibitor, oral/IV, bactericidal, blocks DNA replication in MRSA, PRSP, VRE

DiscoveryLead Opt.IND EnablingPhase IPhase IIPhase III

CRS0393 NTM/TB

MmpL3 inhibitor, blocks cell wall synthesis in nontuberculous Mycobacteria and M. tuberculosis

DiscoveryLead Opt.IND EnablingPhase IPhase IIPhase III

Exploratory

Microbiome modulators (CRS3123), Secondary indications (CRS3123), Gram-negative agents, Antivirals

DiscoveryLead Opt.IND EnablingPhase IPhase IIPhase III

CRS3123 for C. difficile

CRS3123 is a small molecule protein synthesis inhibitor we’re developing and testing to treat C. difficile Infection (CDI), a gastrointestinal condition caused by toxin-producing strains of C. difficile bacteria. Learn more about this promising treatment and sign up for our clinical trials using the link below.

CRS0540 Gram-positives

We are developing a novel class of small molecule antibiotics targeting PolC, the replicative DNA polymerase in Gram-positive bacteria. By inhibiting a novel bacterial target, these compounds circumvent existing mechanisms of antibiotic resistance.

CRS0393 NTM/TB

We are developing a novel class of anti-mycobacterial agents (benzothiazole amides) that target the MmpL3 protein essential for cell wall synthesis. In collaboration with scientists at Colorado State University, the hit-to-lead program has resulted in advanced compounds that show excellent potency against all mycobacteria tested, including multidrug-resistant strains.

Become a Part of These Projects

Interested in helping further our research into novel antibacterial agents? We’d be thrilled to have your help, either as an investor, a team member, or a participant in our ongoing clinical studies.

Inquiries

Have a question or comment? Follow the link below to contact us about general inquiries.

Careers

Find work in a challenging, team-oriented environment with competitive salaries.

Clinical Studies

Learn how you can become part of our ongoing clinical study to fight deadly GI tract infections.